The Motley Fool··Prosper Junior BakinyAbbVie Stock Declines Despite Strong Quarterly Results and Pipeline Growth
AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.
ABBVearnings reportdividend stock